Uppsala professor warns TBE vaccine may need updating

TBE cases in Sweden have tripled over ten years despite rising vaccinations. Åke Lundkvist, professor of virology at Uppsala University, suspects the virus may have changed, reducing vaccine effectiveness. Researchers are now analyzing 12,000 ticks to investigate.

The number of reported TBE cases in Sweden has risen sharply over the past ten years. According to Folkhälsomyndigheten, cases increased from 238 in 2016 to 504 in 2025, with peaks like 595 in 2023 and a low of 274 in 2020. Vaccinations have risen at a similar pace.

Åke Lundkvist, professor of virology at Uppsala University, describes the trend as suspicious. "Something is fishy," he told SVT Nyheter. He suggests the vaccine may be losing effectiveness if the TBE virus has mutated. "The vaccine can become less effective if the virus causing the infection changes," Lundkvist explained.

To clarify, around 12,000 ticks collected by the Swedish public are being sent to Statens veterinärmedicinska anstalt (SVA). They will be analyzed in collaboration with Uppsala University's Zoonoscentret to compare current virus strains with those from previous years and the basis for existing vaccines.

Lundkvist stresses the need for vaccination. "Absolutely not [skip getting vaccinated], the vaccine works and it is the only important remedy we have today. We will find out if it can be even better," he said. The research aims to rule out other causes for the rise.

Articoli correlati

Illustration of a crowded Swedish hospital amid flu surge, with rising case stats displayed.
Immagine generata dall'IA

Number of influenza cases surges in Sweden

Riportato dall'IA Immagine generata dall'IA

Influenza has truly arrived in Sweden. In the first week of the year, 2,131 cases were confirmed, a 22 percent increase from the end of the previous week. The spread is assessed as medium-high level, according to the Public Health Agency.

Flu cases in Sweden have doubled every week since mid-November, driven by the new K variant of the influenza virus. The Public Health Agency reports a rapid increase, with cases rising from 403 to 808 in one week. Severe cases, including deaths and intensive care admissions, have also risen from low levels.

Riportato dall'IA

Researchers in China have developed a potent antibody that could combat severe fever with thrombocytopenia syndrome (SFTS), a tick-borne disease with a mortality rate of up to 30 percent. The discovery offers new hope for tackling this growing threat in East Asia.

The meningitis outbreak in Canterbury, Kent, UK, has escalated with 29 infections and two deaths, prompting mass vaccinations and antibiotics distribution. Authorities warn of possible spread beyond Kent, while Swedish experts advise vigilance.

Riportato dall'IA Verificato

Scientists at the University of Queensland have captured the first near‑atomic, high‑resolution 3D images of the yellow fever virus, detailing how the surface of the long‑used vaccine strain differs from virulent, disease‑causing strains. The work sheds light on how the virus is recognised by the immune system and could support improved vaccines for yellow fever and related mosquito‑borne diseases.

Researchers at UC San Francisco have uncovered evidence showing how the Epstein-Barr virus may trigger immune responses in multiple sclerosis patients. The study reveals elevated levels of virus-targeting immune cells in the nervous systems of those with the disease. These findings, published in Nature Immunology, suggest potential new treatment avenues by targeting the virus.

Riportato dall'IA

Measles infections in the United States hit their highest level in over three decades last year, with 2,242 confirmed cases. A surging outbreak in South Carolina, which has infected more than 600 people since October, threatens to surpass a major incident in West Texas. This development signals another challenging year for public health ahead.

 

 

 

Questo sito web utilizza i cookie

Utilizziamo i cookie per l'analisi per migliorare il nostro sito. Leggi la nostra politica sulla privacy per ulteriori informazioni.
Rifiuta